First left-right comparative study of topical rapamycin vs. vehicle for facial angiofibromas in patients with tuberous sclerosis complex

Dramatic Improvement of Facial Angiofibromas in Tuberous Sclerosis With Topical Rapamycin: Optimizing a Treatment Protocol

(2011) Cynthia M. C. DeKlotz   ARCHIVES OF DERMATOLOGY

Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: A pilot study of four patients

(2011) Rachael S Foster et al.   AUSTRALASIAN JOURNAL OF DERMATOLOGY

A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity

(2011) M. Wataya-Kaneda et al.   BRITISH JOURNAL OF DERMATOLOGY

Treatment of facial angiofibromas with topical application of oral rapamycin solution (1 mg mL−1) in two patients with tuberous sclerosis

(2011) M.M. Mutizwa et al.   BRITISH JOURNAL OF DERMATOLOGY

Sustained clinical effectiveness and favorable safety profile of topical sirolimus for tuberous sclerosis - associated facial angiofibroma

(2011) R. Salido et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Topical Rapamycin

(2010) Anna K. Haemel et al.   ARCHIVES OF DERMATOLOGY

Successful treatment of angiofibromata of tuberous sclerosis complex with rapamycin

(2010) Elizabeth Kaufman McNamara et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis

(2008) G.F.L. Hofbauer et al.   BRITISH JOURNAL OF DERMATOLOGY

Tuberous sclerosis

(2008) Paolo Curatolo et al.   LANCET

Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis

(2008) John J. Bissler et al.   NEW ENGLAND JOURNAL OF MEDICINE